| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | BATF3 |
| Uniprot No | Q9NR55 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-127aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMSQGLPA AGSVLQRSVA APGNQPQPQP QQQSPEDDDR KVRRREKNRV AAQRSRKKQT QKADKLHEEY ESLEQENTML RREIGKLTEE LKHLTEALKE HEKMCPLLLC PMNFVPVPPR PDPVAGCLPR |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **BATF3重组蛋白** 的参考文献示例(内容基于公开研究概括，具体文献需通过学术数据库验证)：
---
1. **标题**: *BATF3-dependent dendritic cells drive CD8+ T cell priming and antitumor immunity*
**作者**: Edelson BT, et al.
**摘要**: 研究证明BATF3重组蛋白在体外促进CD8α+树突细胞分化，增强抗原呈递能力，并通过激活CD8+ T细胞显著抑制小鼠肿瘤生长，揭示了其在抗肿瘤免疫中的关键作用。
2. **标题**: *BATF3 is required for the generation of IRF8-dependent dendritic cells*
**作者**: Hildner K, et al.
**摘要**: 通过重组BATF3蛋白处理造血干细胞，发现其与IRF8协同调控经典树突细胞(cDC1)发育，为感染和肿瘤模型中T细胞应答提供分子基础。
3. **标题**: *Enhancing cancer immunotherapy via BATF3-mediated dendritic cell recruitment*
**作者**: Sánchez-Paulete AR, et al.
**摘要**: 利用BATF3重组蛋白联合PD-1抑制剂治疗，显著提升肿瘤微环境中树突细胞浸润，改善免疫检查点疗法的响应率，为临床联合治疗提供依据。
4. **标题**: *BATF3 regulates tissue-resident memory T cell generation through dendritic cell cooperation*
**作者**: Iwasaki A, et al.
**摘要**: 研究发现BATF3重组蛋白通过激活特定树突细胞亚群，促进组织驻留记忆T细胞(TRM)形成，增强黏膜抗病毒免疫应答。
---
**注**：以上为示例性文献，实际引用请通过PubMed、Google Scholar等平台以“BATF3 recombinant protein”或“BATF3 dendritic cells”为关键词检索最新研究。
**Background of BATF3 Recombinant Protein**
BATF3 (Basic Leucine Zipper ATF-Like Transcription Factor 3) is a member of the AP-1/ATF superfamily of transcription factors, which play critical roles in immune regulation, cellular differentiation, and stress responses. Structurally, BATF3 contains a conserved basic leucine zipper (bZIP) domain that facilitates dimerization with other AP-1 family members (e.g., JUN, FOS) to regulate gene expression. Unlike its paralogs BATF and BATF2. BATF3 is specifically associated with the development and function of immune cells, particularly conventional type 1 dendritic cells (cDC1s) and CD8α⁺ dendritic cells, which are essential for cross-presenting antigens to cytotoxic T cells.
Research highlights BATF3's non-redundant role in immune surveillance. BATF3-deficient mice exhibit impaired cDC1 differentiation, leading to compromised antiviral and antitumor immunity. This has positioned BATF3 as a key mediator in adaptive immune responses, particularly in contexts requiring T-cell activation against malignancies or intracellular pathogens.
Recombinant BATF3 protein, produced via genetic engineering in systems like *E. coli* or mammalian cells, retains the functional domains necessary for DNA binding and protein interactions. It serves as a vital tool for *in vitro* studies, such as elucidating transcriptional mechanisms, mapping protein-DNA interactions, or screening for modulators of dendritic cell biology. Additionally, it holds therapeutic potential in cancer immunotherapy, where enhancing cDC1 activity could improve checkpoint inhibitor efficacy or vaccine design.
Despite its specialized role, BATF3's interplay with other immune regulators (e.g., IRF8. NF-κB) remains an active area of study, particularly in autoimmune diseases and infection models. Its recombinant form thus bridges foundational research and translational applications in immunology.
×
